These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
398 related articles for article (PubMed ID: 31361848)
1. The safety and efficacy of trifluridine-tipiracil for metastatic colorectal cancer: A pharmacy perspective. Chan BM; Hochster HS; Lenz HJ Am J Health Syst Pharm; 2019 Feb; 76(6):339-348. PubMed ID: 31361848 [TBL] [Abstract][Full Text] [Related]
2. Trifluridine/tipiracil: A practical guide to its use in the management of refractory metastatic colorectal cancer in Australia. Price T; Burge M; Chantrill L; Gibbs P; Pavlakis N; Shapiro J; Sjoquist K Asia Pac J Clin Oncol; 2020 Apr; 16 Suppl 1():3-12. PubMed ID: 32348018 [TBL] [Abstract][Full Text] [Related]
3. Adherence, Dosing, and Managing Toxicities With Trifluridine/Tipiracil (TAS-102). Lee JJ; Chu E Clin Colorectal Cancer; 2017 Jun; 16(2):85-92. PubMed ID: 28242161 [TBL] [Abstract][Full Text] [Related]
4. Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer. Kotani D; Kuboki Y; Horasawa S; Kaneko A; Nakamura Y; Kawazoe A; Bando H; Taniguchi H; Shitara K; Kojima T; Tsuji A; Yoshino T BMC Cancer; 2019 Dec; 19(1):1253. PubMed ID: 31881856 [TBL] [Abstract][Full Text] [Related]
5. A systematic review of observational studies of trifluridine/tipiracil (TAS-102) for metastatic colorectal cancer. Andersen SE; Andersen IB; Jensen BV; Pfeiffer P; Ota T; Larsen JS Acta Oncol; 2019 Aug; 58(8):1149-1157. PubMed ID: 31002008 [No Abstract] [Full Text] [Related]
6. The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer. Van Cutsem E; Mayer RJ; Laurent S; Winkler R; Grávalos C; Benavides M; Longo-Munoz F; Portales F; Ciardiello F; Siena S; Yamaguchi K; Muro K; Denda T; Tsuji Y; Makris L; Loehrer P; Lenz HJ; Ohtsu A; Eur J Cancer; 2018 Feb; 90():63-72. PubMed ID: 29274618 [TBL] [Abstract][Full Text] [Related]
7. A novel antimetabolite: TAS-102 for metastatic colorectal cancer. Miyamoto Y; Lenz HJ; Baba H Expert Rev Clin Pharmacol; 2016; 9(3):355-65. PubMed ID: 26677869 [TBL] [Abstract][Full Text] [Related]
8. Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study. Xu J; Kim TW; Shen L; Sriuranpong V; Pan H; Xu R; Guo W; Han SW; Liu T; Park YS; Shi C; Bai Y; Bi F; Ahn JB; Qin S; Li Q; Wu C; Ma D; Lin D; Li J J Clin Oncol; 2018 Feb; 36(4):350-358. PubMed ID: 29215955 [TBL] [Abstract][Full Text] [Related]
9. Trifluridine/tipiracil for the treatment of metastatic gastric cancer. Kawazoe A; Shitara K Expert Rev Gastroenterol Hepatol; 2020 Feb; 14(2):65-70. PubMed ID: 31920125 [No Abstract] [Full Text] [Related]
10. Integrated safety summary for trifluridine/tipiracil (TAS-102). Falcone A; Ohtsu A; Van Cutsem E; Mayer RJ; Buscaglia M; Bendell JC; Kopetz S; Bebeau P; Yoshino T Anticancer Drugs; 2018 Jan; 29(1):89-96. PubMed ID: 29176395 [TBL] [Abstract][Full Text] [Related]
11. Review of metastatic colorectal cancer treatment pathways and early clinical experience of trifluridine/tipiracil in the UK named patient programme. Iveson T; Carter AM; Shiu KK; Spooner C; Stevens D; Mullamitha S BMC Cancer; 2020 Feb; 20(1):91. PubMed ID: 32013902 [TBL] [Abstract][Full Text] [Related]
12. Trifluridine/Tipiracil: A Review in Metastatic Colorectal Cancer. Burness CB; Duggan ST Drugs; 2016 Sep; 76(14):1393-402. PubMed ID: 27568360 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial. Longo-Muñoz F; Argiles G; Tabernero J; Cervantes A; Gravalos C; Pericay C; Gil-Calle S; Mizuguchi H; Carrato-Mena A; Limón ML; Garcia-Carbonero R Clin Transl Oncol; 2017 Feb; 19(2):227-235. PubMed ID: 27443414 [TBL] [Abstract][Full Text] [Related]
14. Phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in patients with metastatic colorectal cancer. Argilés G; André T; Hollebecque A; Calvo A; Dahan L; Cervantes A; Leger C; Amellal N; Fougeray R; Tabernero J Eur J Cancer; 2019 May; 112():12-19. PubMed ID: 30889492 [TBL] [Abstract][Full Text] [Related]
15. Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer. Arrichiello G; Perrone A; Napolitano S; Martini G; De Falco V; Incoronato P; Laterza MM; Facchini G; Famiglietti V; Nacca V; Paragliola F; Napolitano R; Suarato G; Nicastro A; Martinelli E; Ciardiello D; Ciardiello F; Troiani T Target Oncol; 2022 Nov; 17(6):635-642. PubMed ID: 36239883 [TBL] [Abstract][Full Text] [Related]
16. Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer. Sommerhäuser G; Kurreck A; Stintzing S; Heinemann V; von Weikersthal LF; Dechow T; Kaiser F; Karthaus M; Schwaner I; Fuchs M; König A; Roderburg C; Hoyer I; Quante M; Kiani A; Fruehauf S; Müller L; Reinacher-Schick A; Ettrich TJ; Stahler A; Modest DP BMC Cancer; 2022 Jul; 22(1):820. PubMed ID: 35897060 [TBL] [Abstract][Full Text] [Related]
17. The safety of trifluridine and tipiracil for the treatment of metastatic colorectal cancer. Martinez-Perez J; Riesco-Martinez MC; Garcia-Carbonero R Expert Opin Drug Saf; 2018 Jun; 17(6):643-650. PubMed ID: 29745737 [TBL] [Abstract][Full Text] [Related]
18. TAS-102: a novel antimetabolite for the 21st century. Uboha N; Hochster HS Future Oncol; 2016 Jan; 12(2):153-63. PubMed ID: 26616466 [TBL] [Abstract][Full Text] [Related]
19. TAS-102 for the treatment of metastatic colorectal cancer. Salvatore L; Rossini D; Moretto R; Cremolini C; Schirripa M; Antoniotti C; Marmorino F; Loupakis F; Falcone A; Masi G Expert Rev Anticancer Ther; 2015; 15(11):1283-92. PubMed ID: 26509228 [TBL] [Abstract][Full Text] [Related]
20. TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study. Kuboki Y; Nishina T; Shinozaki E; Yamazaki K; Shitara K; Okamoto W; Kajiwara T; Matsumoto T; Tsushima T; Mochizuki N; Nomura S; Doi T; Sato A; Ohtsu A; Yoshino T Lancet Oncol; 2017 Sep; 18(9):1172-1181. PubMed ID: 28760399 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]